Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026Topline Results from North American Phase 3 ...

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million ...

Dollar General Corporation is rated Buy trading at an attractive valuation with solid margin of safety to intrinsic value.

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 ...

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommend ...

Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its ...

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall ...

CNW/ - Mayfair Gold Corp. ("Mayfair", "Mayfair Gold" or the "Company") (TSXV: MFG) (OTCQX: MFGCF) is pleased to announce the ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

All amounts are in Canadian Dollars unless otherwise noted Base Case - US$3,100/oz Au and C$/US$ exchange rate of 1.35: After-Tax NPV (5%): $652 ...

Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular ...